Literature DB >> 15522378

A single intraoperative sub-Tenon's capsule triamcinolone acetonide injection for the treatment of post-cataract surgery inflammation.

Fernando Paganelli1, José A Cardillo, Luiz A S Melo, Anselmo G Oliveira, Mirian Skaf, Rogério A Costa.   

Abstract

PURPOSE: To compare a single intraoperative sub-Tenon's capsule triamcinolone acetonide injection with steroid drops in the treatment of ocular inflammation after cataract surgery.
DESIGN: Randomized, double-masked controlled trial. PARTICIPANTS: A total of 100 patients were randomized prospectively into 2 groups: 50 patients treated with 1% prednisolone eyedrops (control group A) and 50 patients treated with sub-Tenon's capsule triamcinolone (treatment group B).
METHODS: All patients underwent phacoemulsification and intraocular posterior lens implantation. After surgery, patients were randomized to receive either (group B) an intraoperative 40 mg triamcinolone acetonide sub-Tenon's capsule injection or (group A) 1% prednisolone acetate eyedrops, according to the following schedule: 1 drop 4 times daily (week 1), 3 times daily (week 2), 2 times daily (week 3), once daily (week 4). To mask the study, group B received vehicle drops administered on a similar schedule, and group A received an intraoperative sub-Tenon's capsule injection of a 1 ml balanced salt solution. MAIN OUTCOME MEASURES: The main outcome measures included inflammation (cell, flare, ciliary flush), intraocular pressure, and lack of response.
RESULTS: Triamcinolone was shown to have anti-inflammatory efficacy clinically equivalent to conventional 1% prednisolone eyedrops in reducing intraocular inflammation, as measured by clinical methods. Triamcinolone was found to be as safe as the prednisolone in terms of adverse effects, changes in visual acuity, intraocular pressure, and biomicroscopic and ophthalmoscopic variables. On the third, seventh, fourteenth, and twenty-eighth postoperative days, a significantly lower intraocular pressure (P<0.01) was noted in the triamcinolone group than in the prednisolone group.
CONCLUSIONS: A single intraoperative 40-mg triamcinolone acetonide sub-Tenon's capsule injection demonstrated a clinically equivalent therapeutic response and ocular tolerance compared with 1% prednisolone drops in controlling postoperative inflammation after uncomplicated cataract surgery and merits further investigation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15522378     DOI: 10.1016/j.ophtha.2004.04.026

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  5 in total

Review 1.  [Sustainability in ophthalmology : Adaptation to the climate crisis and mitigation].

Authors:  Johannes Birtel; Heinrich Heimann; Hans Hoerauf; Horst Helbig; Christian Schulz; Frank G Holz; Gerd Geerling
Journal:  Ophthalmologie       Date:  2022-04-22

2.  Intracameral dexamethasone reduces inflammation on the first postoperative day after cataract surgery in eyes with and without glaucoma.

Authors:  Diane T W Chang; Michael C Herceg; Richard A Bilonick; Larissa Camejo; Joel S Schuman; Robert J Noecker
Journal:  Clin Ophthalmol       Date:  2009-06-02

3.  Comparative Effectiveness of Three Prophylactic Strategies to Prevent Clinical Macular Edema after Phacoemulsification Surgery.

Authors:  Neal H Shorstein; Liyan Liu; Michael D Waxman; Lisa J Herrinton
Journal:  Ophthalmology       Date:  2015-09-26       Impact factor: 12.079

Review 4.  Drop-free approaches for cataract surgery.

Authors:  Neal H Shorstein; William G Myers
Journal:  Curr Opin Ophthalmol       Date:  2020-01       Impact factor: 4.299

5.  Efficacy of subtenon 20-mg triamcinolone injection versus 0.1% dexamethasone eye drops for controlling inflammation after phacoemulsification: a randomized controlled trial.

Authors:  Pitipol Choopong; Nuttacha Taetrongchit; Sutasinee Boonsopon; Atchariya Nimkarn; Kanyapak Srisukkosalin; Pratuangsri Chonpimai; Waree Nujoi; Krissana Maneephagaphun; Noppakhun Panyayingyong; Nattaporn Tesavibul
Journal:  Sci Rep       Date:  2022-10-01       Impact factor: 4.996

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.